THIS VIDEO IS CURRENTLY UNAVAILABLE. WE APOLOGISE FOR ANY INCONVENIENCE AND HOPE TO MAKE IT AVAILABLE ASAP.
As part of our ongoing seminar series, the Centre of Excellence in Severe Asthma hosted Prof. Andrew Menzies-Gow, for a webinar “Optimising OCS use in severe asthma in the era of biologic agents” on 15 November 2018.
Oral corticosteroid (OCS) treatment is a mainstay add-on therapy for severe asthma. While OCS treatment has many beneficial effects, side-effects also contribute to significant disease burden. Strategies that can reduce OCS use while minimising symptoms are recommended, to limit the lifelong impacts of OCS treatment.
Prof. Menzies-Gow discusses:
Conclusions based on current data indicate:
Professor Andrew Menzies-Gow is the clinical lead for severe asthma and the director of the Lung Division at the Royal Brompton Hospital. He is a Professor of Practice (Respiratory Medicine) at Imperial College where his research interests include novel therapies for severe asthma. He was the chair of the NICE Guideline Development Group for Asthma: Diagnosis and Monitoring and is a member of the Clinical Reference Group for Specialised Adult Respiratory Medicine for NHS England leading on the commissioning of severe asthma services.
Prof. Menzie-Gow’s travel was supported by AstraZeneca
More information about severe asthma medications is also available in the Severe Asthma Toolkit – click here